DIDREX (benzphetamine hydrochloride) by Pfizer is clinical pharmacology benzphetamine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1960.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
DIDREX (benzphetamine hydrochloride) is an oral sympathomimetic amine approved in 1960 for the management of exogenous obesity. It functions as a CNS stimulant and appetite suppressant, though its primary mechanism of action in weight loss remains incompletely understood; additional effects on metabolism and CNS activity may contribute to efficacy.
As a product approaching loss of exclusivity with minimal commercial investment visibility, team size and headcount are likely contracting; positions on this franchise typically involve regulatory maintenance and generic transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Benzphetamine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance…
Worked on DIDREX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DIDREX represents a legacy asset with minimal career trajectory; roles are primarily defensive and maintenance-focused, supporting compliance and generic transition rather than market growth or innovation. Working on this product at Pfizer signals assignment to portfolio consolidation or early-career exposure to mature market dynamics rather than high-visibility brand leadership.